Exciting Developments from Veloxis Pharmaceuticals
Veloxis Pharmaceuticals, Inc., an Asahi Kasei company renowned for its dedication in the pharmaceutical realm, is making waves at the upcoming World Transplant Congress (WTC). This global event provides a platform for some of the most promising research in transplant medicine, and Veloxis is poised to present groundbreaking preclinical data regarding pegrizeprument, also known as VEL-101.
Presentation at the World Transplant Congress
The presentation centers around pegrizeprument, a novel subcutaneous CD28 co-stimulation blocker that is being developed as a crucial therapy in kidney transplantation. The abstract titled "Subcutaneous Administration of a CD28 Co-stimulation Blocker Demonstrates Efficacy in an NHP Model of Kidney Allotransplantation" will be delivered by Daniel Schuster, MD, in a distinguished oral abstract session. This bright mind from Duke University is set to champion the discussions on this innovative therapy.
Key Findings from the Study
The study highlights the significant results achieved through the administration of pegrizeprument in a rigorous non-human primate model of renal transplantation. Compared to the control group that received no immunosuppression, those treated with pegrizeprument demonstrated a remarkable increase in rejection-free survival rates, garnishing attention with a statistics of P=0.0128. In conjunction with standard immunosuppressive care, pegrizeprument also showcased survival rates similar to those treated with tacrolimus, a standard care immunosuppressant. However, it uniquely exhibited a reduction in donor-specific antibodies and hinted at a more favorable safety profile.
Expert Insights
Allan D. Kirk, MD, PhD, who chairs the Surgery Department at Duke University, expressed optimism regarding these findings, emphasizing that they underline the efficacy of pegrizeprument as an innovative immunosuppression treatment that may reduce the overall burdens on patients. Kirk remarked on the remarkable tolerance exhibited in the study towards subcutaneous administration, underscoring the advances in drug delivery methods.
Veloxis's Commitment to Transplantation Innovation
Stacy Wheeler, the Chief Executive Officer at Veloxis, articulated the pride felt within the company to present their research at the World Transplant Congress. This engagement is not just about sharing findings; it's a celebration of the ongoing strides Veloxis is making in transplant healthcare. The opportunity to highlight their work, focusing on improving long-term outcomes for transplant patients, is a significant milestone for the organization.
About the World Transplant Congress
The World Transplant Congress has gained a prestigious reputation in the medical community, dedicated to the science of transplantation. Bringing together scientists, healthcare professionals, and thought leaders, this conference provides educational workshops and networking opportunities to foster advancements in the field. With an expected audience of leaders in transplantation medicine, the event serves as a catalyst for innovation in organ transplant technology and science.
About Pegrizeprument
Pegrizeprument stands out as a pegylated monoclonal antibody designed to inhibit CD28-mediated T cell activation without interrupting CTLA-4 functionalities, a crucial aspect of the immune response. As Veloxis focuses on developing pegrizeprument for not just kidney transplant recipients, but also potentially for other solid organ transplantations, this therapy represents a dual-mechanism of action crucial to advancing transplant medicine.
About Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals is dedicated to enhancing the lives of transplant patients globally. With their commitment to create and commercialize innovative therapies for transplant recipients, they strive to lead in a niche market critical for patient health. Headquartered in Cary, North Carolina, Veloxis actively engages in medical advancements that benefit transplant patients and their health outcomes, continuing to focus on unmet medical needs.
Frequently Asked Questions
What is the focus of Veloxis Pharmaceuticals' presentation?
The focus is on presenting new preclinical data for pegrizeprument, a novel therapy for kidney transplantation, at the World Transplant Congress.
What did the study find regarding pegrizeprument?
The study found that pegrizeprument significantly improved rejection-free survival compared to control groups, indicating its potential effectiveness in transplant therapy.
Who is presenting at the Congress?
Daniel Schuster, MD, will be presenting the groundbreaking findings about pegrizeprument at the World Transplant Congress.
What is the significance of the World Transplant Congress?
It serves as a premier global event to discuss and advance the science and medicine related to transplantation, featuring leading experts in the field.
How is Veloxis Pharmaceuticals contributing to transplant medicine?
Veloxis is committed to improving transplant patient outcomes through innovative therapies and research development.
